Top Tweets for #LENALIDOMIDE
Generic #Lenalidomide use increased after market entry, but it remained a minority of treatment starts and many generic initiators switched formulations within 6 months.
https://t.co/dQMGqevKnO

🔴 Our live Q&A is underway at Blood Cancers OncTalk 2026!
First up: a question about #lenalidomide’s safety and concerns about reports patients may have heard. Our experts are discussing how to understand treatment benefits and risks.
💬 Join us now to hear the discussion and bring your questions! It’s free:
https://t.co/FJARYyLNA7
#BloodCancer #MultipleMyeloma #GRACE #OncTalk
13) Structurally, that translates into cereblon ~50% active with #iberdomide vs ~20% with #lenalidomide. Practical consequences: more potent #MM cell killing, retained activity in #IMiD-resistant disease, & enhanced immune stimulation. #CELMoD

❓Does continuous #lenalidomide maintenance improve survival for standard-risk #MultipleMyeloma?
Randomized trial data from @NEJM showed a 2️⃣-year regimen produced similar overall & progression-free survival as indefinite therapy.
https://t.co/z4Z6PjFLHL
🗓️ Patients with standard-risk #MultipleMyeloma who receive 2 years of #lenalidomide maintenance survive as long as those who get indefinite therapy.
🗨️ “The trial makes a compelling argument to pursue limited-duration therapy,” @myelomaMD @mayoclinic
https://t.co/BQq1LPTT2G
Highly recommended: With a median follow-up of 7 years, overall survival rates in the ENDURANCE study (E1A11) were 69.0% in patients who continued lenalidomide until disease progression and 68.6% in those who stopped after 2 years.
#lenalidomide https://t.co/a4rHGAEAHq
In our ongoing Multiple Myeloma series we had a chance to 🗣️ #ENDURANCE trial w/ @myelomaMD & @VincentRK
✅ New SoC duration for Maintenance
✅ Can we extrapolate to other pts?
Full 🗣️:
⭐️ https://t.co/PsrPY0iMxN
⭐️ “Oncology Brothers” podcast
#OncTwitter #HemeTwitter
📢European Commission Update on #epcoritamab in combination with #lenalidomide and #rituximab for relapsed/refractory follicular #lymphoma.
#follicularlymphoma #europeancommision #medicinalchemistry #pharmanews #PharmaIndustry
💊Approval Update | The European Commission has approved #TEPKINLY (#epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory #FollicularLymphoma after at least one prior line of therapy.
💡Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody that redirects T cells to eliminate malignant B cells
📊Phase 3 EPCORE FL-1:
🔹79% reduction in the risk of disease progression or death vs #lenalidomide + #rituximab alone
🔹Overall response rate: 96% vs 81%
🔹Complete response rate: 74% vs 43%
#EuropeanCommission #Hematology #Lymphoma #BispecificAntibody #Immunotherapy #Oncology #CancerResearch #DrugDiscovery #MedicinalChemistry

7) Those guidelines stratify patients based on their baseline #erythropoietin levels. Patients with low levels may benefit from #ESAs, while those with higher erythropoietin levels may explore other options, such as #danazol, #lenalidomide, #thalidomide, or #luspatercept.
@SagarLonialMD @MyelomaDrKapoor @MayoClinic @unmc 48) #Lenalidomide maintenance post-#ASCT is #SOC in #MM, but ~30% of pts d/c within 1y due to toxicity. Could #iberdomide, a more potent oral #CELMoD, offer a better-tolerated and more effective alternative? A Ph 2 trial reports its primary analysis. #ASCO2026

6a) #CELMoD agents (Cereblon E3 Ligase Modulators) are next-generation descendants of #IMiDs like #thalidomide, #lenalidomide, and #pomalidomide. In #MM, they act as “molecular glue degraders,” binding #CRBN . . .
Adding #tafasitamab and #lenalidomide to R-CHOP for first-line treatment can reduce the risk of disease progression or death in patients with #DLBCL, according to new research at #ASCO26. https://t.co/b9cGw2Va6g

Among patients with follicular #lymphoma, adding #epcoritamab to the SOC combo of #lenalidomide plus #rituximab outperformed lenalidomide plus rituximab alone, resulting in ORRs of 95% vs. 79%, as well as a lower risk of disease progression or death: https://t.co/n9b4WDFIUW
Important step to improve newly diagnosed DLBCL patients outcome. frontMIND shows 25% risk reduction of death or progression. After inMIND (Lancet. 2025 Dec 5:S0140-6736(25)01778-7) another positive #tafasitamab and #lenalidomide
We’ve announced positive topline results from the Phase 3 frontMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Read our press release to learn more. https://t.co/3LIrL1NYOF
Reem Hal Shares New Clinical Capsule: Thrombosis in Cancer Patients
https://t.co/d0eaD0nknK
#ClinicalCapsule #Dexamethasone #Health #MedEd #MedX #Hemostasis #HemostasisToday #lenalidomide #Medicine #Thrombosis #ThromboticRisk
New @BloodAdvances paper: "#MRD-driven Initial Therapy of #Acalabrutinib and #Lenalidomide plus #Rituximab or #Obinutuzumab for Mantle Cell #Lymphoma," by WCM's Dr. Jia Ruan with @WCMCPathology Drs. Giorgio Inghirami and Selina Chen-Kiang (@Konadecaf)!
https://t.co/XFLtHOrWT3

New @BloodAdvances: "#MRD-driven Initial Therapy of #Acalabrutinib and #Lenalidomide plus #Rituximab or #Obinutuzumab for Mantle Cell #Lymphoma," by Dr. Jia Ruan with @WCMEnglanderIPM's @ElementoLab, @BhavneetBhinder, Michael Sigouros, and @JohnPLeonardMD
https://t.co/i2YwvIODET

#ESMO25: New research reveals that sustained MRD negativity after #ASCT allows safe discontinuation of #lenalidomide maintenance in multiple #myeloma patients. https://t.co/5yxTK12yEQ
@FDAOncology However, the Danish Medicines Council @LMSTdk has recommended to not use Lenalidomide at all for any age.
So the drugs that are lethal are #Pomalyst #Pomalidomide #Revlimid #Lenalidomide #IMiD and they are manufactured by Celgene and the Bristol Myers Squibb $BMY from USA.
#MultipleMyelomaAwareness @myeloma_today
WARNING: #Pomalyst #Pomalidomide #Revlimid #Lenalidomide #IMiD are lethal for patient with a biological age older than 65 years.
You have to use https://t.co/N6hxy2tVMb in order to read this Swedish article.
https://t.co/Eetd5FjQfW
LUPIN LIMITED – US FDA APPROVAL ✅
Received approval for Lenalidomide Capsules (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg & 25 mg), bioequivalent to Revlimid, a key oncology drug
▶️ Estimated annual U.S. sales: USD 7,511 million (IQVIA MAT July 2025)
#LUPIN #FDAApproval #Lenalidomide #Revlimid #Oncology #USMarket
Last Seen Hashtags on Sotwe
bbc #babecock
Seen from United States
GTA6
Seen from Mexico
familyfantasy
Seen from India
MGAI(*)**(**)
Seen from United States
babecock
Seen from United States
ควยทหาร
Seen from Thailand
snapchattt
Seen from Turkey
brosis
Seen from Colombia
verityxmob
Seen from United States
ดอนเมือง
Seen from Thailand
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
240.5M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.3M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers

















